University of Pennsylvania researcher Carl June is back with another impressive round of results for a much larger group of patients in what is fast becoming a race to the finish line with one of the most promising new leukemia therapies in the clinic.
Here's FierceBiotech's pick of the top 10 biotech IPOs in 2013. These are companies that reaped major rewards for backers and executives. Editor-in-chief John Carroll used a mix of the IPO price compared to the range plus the amount raised and the subsequent increase in share price to make his selection. It's also a somewhat subjective selection and listing, and readers are encouraged to comment on the list and companies they might have preferred.
For the record, this a snapshot of where we are today when it comes to defining the 2013 version of what's trendy in biotech. Twenty years from now you can either look back and see the bottom floor or glimpse the elevator doors that opened directly to the shaft. You'll find a link at the bottom that will jump to the full list of 39 IPOs and 14 pitches of the year--biotech and diagnostics only, no devices or ag bio--and how their stock has performed as of the close late last week.
FierceBiotech is now available on iPhone and iPad!
This is the best FierceBiotech reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Android users: We're on track to have an app complete by the end of the year.
Have something to say? Join the conversation at
FierceBiotech's LinkedIn group.
POPULAR COMMENT THREADS
Tomorrow Merck will take its best shot at convincing a group of FDA advisers that its sublingual allergy pill Grastek deserves a place in the nation's pharmacies.
Back in January, Jeremy Levin--then riding high as CEO of Teva--didn't think much of the company's program for an immune checkpoint receptor drug dubbed CT-011, or pidilizumab
ImmunoCellular Therapeutics put out the word Wednesday afternoon that its dendritic cell-based vaccine for brain cancer flunked the key overall survival test in Phase II, news that swiftly wiped out more than half of the small biotech's market cap as shares instantly cratered.
Prothena's PRX002, a preclinical treatment targeting Parkinson's disease, is at the heart of a deal with Swiss pharma giant Roche, worth up to $600 million plus 30% of U.S. profits to the Irish biotech.
The FDA has shrugged off Sprout Pharmaceuticals' female libido drug, further delaying the years-long quest to develop a Viagra equivalent for women, but the drugmaker is appealing the rejection, arguing that the agency is misunderstanding how to measure efficacy.
Avanir Pharmaceuticals watched its shares tank more than 20% after its lead pain candidate failed to outdo a placebo in a Phase II study of patients with multiple sclerosis.
From Our Sister Sites
Cymbalta is going down. The question for Eli Lilly is how fast and how far. Last evening, the FDA approved more than a half-dozen generic versions of Cymbalta, the antidepressant that's now Lilly's top-selling drug.
St. Jude Medical won a long-awaited CE mark for a larger size of its Portico transcathether aortic heart valve implant, a milestone that expands its overseas market reach and ups competitive pressures on rivals Edwards Lifesciences, Medtronic and Boston Scientific.